Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2025)

Maravai Lifesciences Holdings has reported EBITDA Margin over the past 6 years, most recently at 117.91% for Q4 2025.

  • Quarterly results put EBITDA Margin at 117.91% for Q4 2025, down 5125.0% from a year ago — trailing twelve months through Dec 2025 was 115.89% (down 2499.0% YoY), and the annual figure for FY2025 was 115.89%, down 2499.0%.
  • EBITDA Margin for Q4 2025 was 117.91% at Maravai Lifesciences Holdings, down from 98.56% in the prior quarter.
  • Over the last five years, EBITDA Margin for MRVI hit a ceiling of 75.87% in Q3 2021 and a floor of 239.93% in Q3 2024.
  • Median EBITDA Margin over the past 5 years was 13.25% (2023), compared with a mean of 16.5%.
  • Biggest five-year swings in EBITDA Margin: plummeted -21688bps in 2024 and later skyrocketed 14137bps in 2025.
  • Maravai Lifesciences Holdings' EBITDA Margin stood at 67.65% in 2021, then dropped by -21bps to 53.37% in 2022, then crashed by -118bps to 9.64% in 2023, then crashed by -591bps to 66.66% in 2024, then plummeted by -77bps to 117.91% in 2025.
  • The last three reported values for EBITDA Margin were 117.91% (Q4 2025), 98.56% (Q3 2025), and 139.84% (Q2 2025) per Business Quant data.